(R)-(+)-Etomoxir sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1(CPT-1)[1].

Etomoxir (100 μM) has no effect on T cells cultured in high glucose. In contrast, there is a significant increase in apoptosis in etomoxir-treated cultures stimulated with antigen under low glucose conditions[2].

C57BL/6 mice treated with Etomoxir (15 mg/kg, i.p) reduce the infiltration of immune cells in the central nervous system. Only a small number of macrophages, activated microglia or T cells are present, while reducing the inflammatory response and Demyelinating reaction[2].

References:

[1]. Rupp H, Zarain-Herzberg A, Maisch B. The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure. Herz, 2002, 27(7): 621-636.

[2]. Shriver L P, Manchester M. Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Scientific Reports, 2011, 1.